Biosimilar development hinges on one central challenge: demonstrating that a proposed biosimilar is highly similar to its reference product and that any differences do not meaningfully affect safety, purity, or potency.
Doing so requires more than completing individual analytical studies or regulatory milestones. Development planning, analytical characterization, manufacturing, supporting studies, and FDA engagement must reinforce the same scientific argument.
The totality of evidence provides the foundation for this approach. Rather than relying on any single study or data point, sponsors build an integrated evidence package that demonstrates similarity and progressively addresses areas of uncertainty.
The following six steps can help sponsors build a stronger biosimilar development and comparability strategy from early planning through FDA submission.
Step 1: Build the biosimilar development plan around comparability
Comparability should shape the biosimilar development strategy from the beginning. FDA considers the totality of data and information submitted when evaluating a sponsor’s demonstration of biosimilarity, making early alignment across development activities critical.
A well-constructed plan should address:
- Reference product selection and sourcing
- Proposed indication or indications
- Comparative analytical assessment strategy
- Potential development and regulatory risks
- Evidence needed to demonstrate similarity
- Questions that require early FDA feedback
These decisions also establish the foundation for initial FDA interactions.
Rather than treating analytical, manufacturing, clinical, and regulatory planning as separate workstreams, sponsors should organize them around one question: How convincingly will the development program demonstrate similarity to the reference product?
Step 2: Understand the molecule and establish its analytical fingerprint
Biological molecules can exhibit multiple structural variations. Sponsors need to characterize those variations and understand whether they could affect product function relative to the reference product.
This starts with identifying the critical quality attributes (CQAs) most relevant to product quality and performance. Depending on the molecule, these may relate to molecular structure, post-translational modifications, heterogeneity, biological activity, product function, and other characteristics with potential implications for safety or efficacy.
Sponsors then need an analytical strategy capable of creating a detailed fingerprint of the proposed biosimilar and reference product. Because no single assay can fully characterize a complex biological product, this typically requires complementary and orthogonal analytical methods.
Examples include:
| Attribute | What you're evaluating | Example analytical approaches |
|---|---|---|
| Primary structure | Amino acid sequence | Proteomics-based sequencing, mass spectrometry |
| Higher-order structure | Secondary/tertiary structure | Appropriate structural characterization methods |
| Charge/size heterogeneity | Variants and aggregates | IEF, PAGE, other separation methods |
| Glycosylation | Glycan profile | Glycan analysis |
| Function | Biological activity/binding | Antigen-antibody binding and functional assays |
The objective is not simply to generate more analytical data, but to establish a sufficiently detailed picture of the molecule to support meaningful comparison.
Step 3: Build a robust comparative analytical assessment
With the analytical fingerprint established, sponsors can evaluate how closely the proposed biosimilar matches the reference product.
A robust comparative analytical assessment may examine primary amino acid sequence, secondary and tertiary structure, post-translational modifications, glycosylation, size and aggregation, charge, hydrophobicity, binding characteristics, biological activity, and product- and process-related impurities. Techniques can include proteomics-based sequencing, mass spectrometry, IEF, PAGE, glycan analysis, dynamic light scattering, and antigen-antibody binding studies.
The strength of the assessment comes from interpreting these results collectively. Multiple complementary methods can provide a more convincing demonstration of similarity than any individual result.
Just as importantly, sponsors need to investigate observed differences in context. A difference in an analytical attribute may require further characterization to determine whether it could have functional or clinical significance.
Step 4: Maintain comparability as the manufacturing process scales
Comparability cannot be separated from process development. Sponsors also need confidence that the manufacturing process can consistently produce material with the intended quality profile as the program moves toward larger-scale and commercial manufacturing.
That requires understanding whether changes in process parameters, equipment, materials, or scale could affect CQAs such as glycosylation, aggregation, impurity levels, or biological activity.
Throughout process development, scale-up, technology transfer, and manufacturing changes, sponsors should continue evaluating whether the biosimilar maintains its expected structural and functional characteristics relative to the reference product.
The key principle is simple: comparability is not demonstrated once and then assumed. Process understanding and control must support consistent product quality throughout development and scale-up.
Step 5: Identify and address residual uncertainty
Even highly similar biological products may have small differences from their reference products. The development program must identify those differences and determine whether they could affect safety, potency, efficacy, or other clinically relevant characteristics.
This is where sponsors address residual uncertainty.
A risk-based approach starts by identifying the difference, assessing its potential significance, and then determining what additional evidence is needed to resolve the remaining question. Depending on the issue, that evidence may include:
- In vitro pharmacology or in vivo efficacy studies
- PK/PD assessment
- Toxicology and toxicokinetic studies
- Immunogenicity and cross-reactivity evaluation
- Formulation and stability assessment
- Sterility considerations
The goal should not be to accumulate data for its own sake. Additional studies should address specific areas of uncertainty and strengthen the overall demonstration of biosimilarity.
Step 6: Use FDA interactions strategically throughout development
FDA engagement should be an ongoing component of the biosimilar development strategy rather than a final step before submission.
Early interactions are most productive when sponsors arrive with a clearly defined development plan, reference product and indication strategy, comparative analytical assessment approach, known risks, and specific questions for FDA.
As development progresses, Biosimilar Product Development (BPD) Type 2 and Type 3 meetings provide opportunities to obtain FDA feedback on development and regulatory issues. Targeted questions can help sponsors address uncertainty, refine development approaches, and identify potential gaps before they become costly late-stage problems.
As the program approaches submission, the evidence should tell a consistent story:
Product understanding → analytical similarity → manufacturing consistency → resolution of residual uncertainty → totality of evidence
Together, these elements help prepare the sponsor for the BPD Type 4 meeting and eventual 351(k) biosimilar application.
Build a totality of evidence that tells one consistent story
Successful biosimilar development is not defined by a single analytical result, manufacturing milestone, study, or FDA meeting. It depends on how convincingly the complete evidence package demonstrates similarity to the reference product.
By aligning development planning, CQAs, analytical characterization, manufacturing and scale-up, residual uncertainty assessment, and regulatory engagement, sponsors can identify gaps earlier and approach FDA interactions with a clearer scientific rationale.
Ultimately, the goal is not simply to generate more evidence. It is to generate the right evidence at the right stage of development to progressively build confidence in biosimilarity.
Strengthen your biosimilar CMC and regulatory strategy with Pharmatech Associates
Pharmatech Associates helps biosimilar developers align development, analytical, manufacturing, and regulatory strategies to support a convincing demonstration of comparability.
Our experts can help identify development risks, strengthen evidence packages, and prepare teams for FDA interactions from early development through submission.
Planning a biosimilar development program or preparing for an upcoming FDA interaction? Talk to one of Pharmatech’s experts.
